Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has been issued a notification of intention to grant from the Australian Patent Office for its patent Family 3 'Anti-Virus Agent and Method for Treatment of Viral Infection'.
This is the final patent of Family 3, following those already granted in the biggest pharmaceutical markets in the world such as China, Japan, Europe and Hong Kong.
The Australian patent claims related to RECCE® 327 (R327) and anti-viral formulation RECCE® 529 (R529), include:
- Composition/method of manufacture of RECCE® anti-infectives;
- Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and Corona viruses, Influenza viruses, HIV, Hepatitis, Ross River and Herpes viruses; and
- Administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications
Recce CEO James Graham said: “Receiving notice that this Australian patent application will proceed to grant is another milestone in the company’s global IP strategy and we are thrilled by the yet further validation to the potential importance of our infectious disease compounds.”
Anti-infective pipeline
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives.
RECCE 327 is an intravenous and topical therapy being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms.
RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections.
Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.